Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Earnings Neutral

Cresco Labs Reports First Quarter 2026 Financial Results, Advances Multiple Growth Initiatives

Cresco Labs Q1 Earnings Show Revenue Stagnation Despite Regulatory Tailwinds and Texas License Award

By The Northwire Desk — AI Analysis May 08, 2026 · 06:30 CL · 1.5 Cresco Labs Inc.
Executive Summary
  • Q1 2026 Financial Performance: Reported revenue of $151.3 million, down from $162 million in Q4 2025 and $165 million in Q3 2025. Adjusted EBITDA was $32.9 million (21.7% margin), down from $40 million in Q4 2025.
  • Net Loss: Reported a net loss of ($17.0 million) for the quarter, significantly improved from the ($89.0 million) loss in Q4 2025 driven by non-cash impairment charges.
  • Cash Position: Cash and equivalents dropped to $67 million as of March 31, 2026, down from $91 million at year-end 2025, indicating a cash burn of approximately $24 million during the quarter despite positive EBITDA.
  • Debt Profile: Senior secured term loan stands at $310 million with a mortgage loan of $19 million. Interest rate on term loan is 12.5% (refinanced in Q3 2025).
  • Operational Expansion: Opened two new dispensaries in Ohio, commenced management services in Pennsylvania, and completed first harvest in Kentucky.
  • Regulatory Milestones: Received a conditional award for a Texas Compassionate Use Program license. U.S. Department of Justice finalized rescheduling medical marijuana to Schedule III, expected to eliminate Section 280E tax implications for medical operations.
Material Impact
  • Revenue Decline Concerns: The sequential revenue decline ($165M -> $162M -> $151M) is a negative signal that contradicts the growth narrative often associated with expansion into new states like Texas and Kentucky. This suggests either market saturation in core regions or execution delays in monetizing new licenses.
  • Cash Burn vs. Liquidity: The reduction of cash reserves from $91 million to $67 million within one quarter is a critical risk factor given the high debt load ($329M total). While not an immediate solvency crisis, it limits flexibility for further acquisitions or unexpected downturns without raising capital (ATM program available but dilutive).
  • Regulatory Tailwinds: The Schedule III rescheduling and Texas license are material long-term positives. However, the Texas award is "conditional," meaning final approval steps remain pending, delaying immediate revenue recognition from that market.
  • Earnings Quality: The improvement in net loss ($89M to $17M) was primarily due to the cessation of impairment charges rather than operational profitability growth. Adjusted EBITDA margin compression (25% -> 21.7%) indicates cost pressures or lower utilization rates on new assets.
  • Transcript Discrepancy: The provided transcript data referenced Colgate-Palmolive and was excluded from this analysis to maintain factual integrity regarding Cresco Labs' financials.
CL · Price
Company Overview
  • Company: Cresco Labs Inc., one of the largest vertically integrated cannabis operators in the U.S.
  • Flagship Project/Strategy: State-by-state expansion focusing on high-value markets (Ohio, Pennsylvania, Texas) while maintaining core operations in Illinois and Michigan.
  • Brand Portfolio: Includes Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, Remedi, and Sunnyside dispensary network.
  • International Expansion: Launched flower brand in Germany (Nov 2025) as a pilot for EU market entry via prescription channels.
Read the original news release →

More from Cresco Labs Inc.

Jun 08, 2026 · 06:00

Cresco Labs Closes US$50 Million Revolving Credit Facility with Needham Bank

Financings May 27, 2026 · 06:30

DEA Registration Puts Federal Imprimatur on Cresco’s Medical Operations, but Texas Setback Clouds Growth Ambitions

Regulatory May 11, 2026 · 06:30

Texas Regulator Pulls Back Cresco’s Conditional License, Clouding a Key Growth Catalyst

Regulatory Apr 23, 2026 · 13:24

Federal Rescheduling Validates Business Model, But Debt Overhang Remains Key Risk

Regulatory Apr 02, 2026 · 19:21

Cresco Labs receives Texas medical cannabis licence

Other Apr 02, 2026 · 14:26

Cresco Labs Awarded Texas Medical Cannabis License

Regulatory